Tool to stimulate natural resistance and prevention of gastrointestinal diseases calves


(57) Abstract:

The invention relates to animal husbandry, in particular to the means immune stimulation and prevention of gastrointestinal diseases of newborn calves. Essence: apply ksimedon, which is on the 2nd and 10th days of newborn calves intravenous 0.15 g per 10 ml of saline. The drug stimulates the natural resistance of the organism, increases the protective function of the mucosa of the gastrointestinal tract and respiratory organs, suppresses the conditional and pathogens, which ultimately leads to disease prevention and increase animal productivity.

The invention relates to animal husbandry, in particular to the means immune stimulation and prevention of gastrointestinal diseases of newborn calves.

Known methods for enhancing the natural resistance of the animal body, consisting in the application of procaine blockade [1,2] subcutaneous injection of drugs T and B activin [3,4] the use of gamma globulin, protein hydrolysates, tarirovannoj blood, autohemotherapy [5,6,7] For the prevention and treatment of gastrointestinal diseases applied inside and intramuscular antibiotics, sulfanyl the ur (ABA), propionato-acidophilus broth culture (PABK), acidophilus, acidophilus milk [10,11,12] gastric juice horses, rennet juice calves and their artificial analogues [13,14, 15]

The disadvantage of these tools is the one-sidedness of their actions, that requires the integrated application. This increases the time and cost of preventive and therapeutic courses with insufficient because of the adaptation of conditionally pathogenic microflora.

Known drug ksimedon-N-(-hydroxyethyl)-4,6-dimethylpyrimidin 2; C8H12N2O2as burns funds. The structural formula of Ximena:

< / BR>
The purpose of the invention the expansion of the range of funds immunostimulation and prevention of gastrointestinal diseases of newborn calves.

The objective is achieved by using Ximena as a means of stimulation of natural resistance and prevention of gastrointestinal diseases of newborn calves.

The essence of the application of Ximena consists in the following. Newborn calves on the 2nd (after 2/3 receptions colostrum) and the 10th day after birth in 10 ml of saline intravenously injected 0.15 grams of the drug.

Example. Newborn calves on the principle of analogues were formed into two groups (experimental and control) for 30 goals each. Conditions of feeding, care and maintenance in both groups the same. The calves of the experimental group on the 2nd and 10th day after birth intravenously in 10 ml of saline was injected 0.15 g Ximena, the calves of the control group and inside intramuscularly applied portirovanie antibiotics (methodology applied in the farms of the area). In the 1st and 20th days of the experimental and control calves took blood samples and have identified the following indicators of the natural resistance of the organism: total protein, calcium, phosphorus, IIIP, II oxycorticosteroid, phagocytic (F), bactericidal (BA) the authors estimated the effect activity of blood, immunoglobulins and sportactivities.

The obtained results show that the use of Ximena causes experienced calves increase in blood total protein 26% (6,02 to 7,63 g), the control calves growth was only 4% (of 5.92 to 6.14) g Quantitative indicator of calcium in the application of Ximena increased by 31% in the control calves indicator of this component of the blood remains at the same level. The rate of phosphorus in experimental calves increased by 9% and controllery activity by 31% bactericidal and lysozyme activity of the blood, respectively, 38 and 29%

The control calves these indicators remained at the same low against the physiological norm.

Figure II-ACS experienced calves is reduced to physiological hormone levels (from 5.6 to 4 mg), which indicates good adaptation capabilities of the organism of animals. The control calves, the figure rises to 5.7 mg what characterizes high tension metabolism and depletion of adaptation mechanisms of the body of calves.

Experienced calves quantitative indicator of immunoglobulins exceed 15 mg/ml, which caused the development of effective immunity to environmental microflora. The control calves this figure is below 5 mg/ml, as a result, they become susceptible even to conditionally pathogenic microorganisms. Therefore, ksimedon has a well-pronounced stimulating effect on the natural resistance of the organism calves, which determines their resistance to disease and increase productivity.

Preventive action Ximena for gastro-intestinal diseases is determined in the same production experience.

Clinical observation of experienced calves and controllerservlet cases of communicable and non-communicable diseases, the weight gain of the animals.

Example. The average weight gain of calves in days age in the experimental group was 26.4 kg in the control to 26.7 kg per month of age calves from the experimental group had an average of 40.8 kg (average daily gain 480 g), in the control and 30 kg (average daily gain 110 g). Minusa weight of dead calves, total weight gain in the experimental group was 391,2 kg in the control only 39 kg In the experimental group cases of colibacillosis is not registered. Was one case of salmonellosis (3% ) and two cases of parainfluenza (6%). The use of appropriate serums and treatment provided recovery calves. Six goals in this group had a simple dyspepsia. The appropriate diet provided the normalization of digestive functions without the cost of drugs.

In the control group registered and confirmed by bacteriological examination, 3 cases of colibacillosis, 6 cases of salmonellosis and 12 cases of infectious bovine rhinotracheitis. All calves were ill with gastrointestinal disorders, 12 goals was registered bronchopneumonia. Despite the action taken in time of treatment, 9 calves were killed.

Production testing of the proposed funds held in CoII

1. Shakurov N. W. Naplavlena novocaine blockade "chest" sympathetic nerves. In kN. abstracts of all-Union conference, dedicated to the 100th anniversary K. C. I.

2. Procaine therapy in veterinary practice. Kirov, 1979

3. Interim guidance on the application of T-activin. Approved BS Gosagroprom USSR, N 433-7, from 04.01.88.

4. Interim guidance on the application of B-actine. Approved BS Gosagroprom USSR, N 434-7, from 04.01.88.

5. Kalnin Century, Gamma-globulin preparations warn dyspepsia calves. Veterinary medicine, 3, 1970

6. Chernukha Century as the Use of non-specific gamma-globulin in dyspepsia newborn calves. In kN. "Prevention and treatment of non-communicable diseases of young farm animals", M. 1968

7. Mawson-Zadeh K. K. the Use of protein hydrolysates in the treatment and prevention of internal non-infectious diseases of young animals. In kN. "Prevention and treatment of non-communicable diseases of young animals agricultural animals", M. 1968

8. Aliyev Century A. Dyspepsia. In kN. "Internal non-communicable diseases of agricultural animals", M. 1964

9. Podkopaev Century. N. Dose determination of antibiotic toxic dyspepsia calves. Veterinary medicine, 4, 1965

10. A. Dyspepsia calves. In kN. "The achievements of veterinary science", ed. "Spike, M. 1966

12. Mironov, C. D. Effect of acidophilus corn silage on rennet secretion in calves. WPI. Academy of Sciences of the Kazakh SSR, 1964, N 6.

13. Smirnov A. M. Natural gastric juice horses a highly effective remedy for gastro-intestinal and other diseases of young farm animals. In kN. Prevention and treatment of diseases of agricultural animals. M. 1968

14. Karamov H. K. Mushin M. The effectiveness of gastric juice. Veterinary medicine, 11, 1966

15. Khairutdinov H. W. and co-authors. The preparation and use of rennet juice cattle. Veterinary medicine, 10, 1967

16. Ksimedon. Scientific compendium of experimental and clinical trials, IOPC them. A. E. Arbuzov and Kazan medical Institute n.a. Century Century Kurashov, Kazan, 1986

The use of N-(-hydroxyethyl)-4,6-dimethylpyrimidin-2 as a means to stimulate natural resistance and prevention of gastrointestinal and respiratory diseases in calves.


Same patents:

The invention relates to heterocyclic compounds, specifically to piperazine derivatives, in which the piperazine one nitrogen atom is linked to a fragment of aryloxy or aaltio link oxypropylene or alkanoyloxy, and through another nitrogen atom with the rest of acetanilide

The invention relates to 9-amino-1,2,3,4-tetrahydropyridines and related compounds of the formula I

< / BR>
in which Y is C= O or CHOH; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl or phenyl-lower alkyl; R3is hydrogen, OR4in which R4is hydrogen, COR5in which R5is lower alkyl, X is hydrogen, lower alkyl, halogen, lower alkoxy-, hydroxy-group or trifluoromethyl, their geometric or optical isomers, N-oxides, or their pharmaceutically acceptable salts and accessions acids (acid additive salts), which are useful in reducing dysfunction in memory and are thus indicative for the treatment of disease Allgamer

The invention relates to a new monohydrate 5- (2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinil)ethyl)-6-chloro-1,3 - dihydro-2H-indol-2-he hydrochloride, containing pharmaceutical compositions, and method of neuroleptic treatment of diseases with the use of the specified monohydrate

The invention relates to medicine, namely to psychiatry and neurology

The invention relates to new biologically active compounds 2-piperazinone, namely 3-(21-naphthylmethyl)-piperazine-2-ONU (I) and 1-N-ventilationperfusion-2-ONU (II) formula:

< / BR>
I R 2-naphthyl; RI=H;


-phenylpiperazine)ethyl] benzamide, possessing neuroleptic activity, and 3 - methyl-n-[2-(4-phenylpiperazine)ethyl]benzamide as a starting compound for the synthesis of" target="_blank">

The invention relates to new chemical compounds of the hydrochloride of 3-methyl-N-[2-(4-phenylpiperazine)ethyl]benzo - foreign formula I

< / BR>
(I) possessing neuroleptic activity, and 3-methyl-N-[2-(4-phenylpiperazine)ethyl] benzamide as starting compounds in the synthesis of hydrochloride of 3-methyl-N-[2-(4-phenylpiperazine)ethyl]benzo - Mead

The invention relates to new Daminova compounds and their acid additive salts and cerebral protective medicines containing these compounds or their salts, more particularly to Daminova compounds and their acid additive salts, which are characterized by excellent cerebral protective effect and are used as medicines in the treatment of disorders of cerebral function or to prevent the development of such disorders, and cerebral protective medicines containing diamino compounds or their acid additive salt

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new sulfur-containing compounds of the formula (I):

their pharmaceutically acceptable salts or solvates, or salt solvates wherein R1 represents (C1-C6)-alkyl, cycloalkyl, aryl, aliphatic or aromatic heterocyclyl substituted with one more basic group, such as amino-, amidino- and/or guanidine-group; R2 represents hydrogen atom (H), alkyl, alkylthio-, alkoxy- or cycloalkyl group; R3 represents COOR5, SO(OR5), SOR5 and others; R4 represents hydrogen atom (H) or (C1-C6)-alkyl; R6 represents hydrogen atom (H); X represents C(Z)2 or NR6CO; Y represents C(Z)2; Z represents hydrogen atom (H), (C1-C6)-alkyl, aryl or cycloalkyl. Indicated compounds inhibit activity of carboxypeptidase U and can be used for prophylaxis and treatment of diseases associated with carboxypeptidase U.

EFFECT: improved preparing method, valuable biochemical and medicinal properties of compounds.

14 cl, 36 ex

FIELD: medicine, oncohematology.

SUBSTANCE: the present innovation deals with treating elderly patients with chronic lympholeukosis accompanied with cardiovascular failure. The method deals with applying chemopreparations and cytoprotector. Moreover, 1 wk before the onset of chemotherapeutic therapy one should prescribe preductal at the dosage of 105 mg daily. At this background one should sample blood out of elbow vein at the volume of 200 ml into a vial with glugicir to centrifuge it, isolate plasma, divide into two portions, add into the 1st vial - cyclophosphan 600-800 mg/sq. m, vincristin 1.4 mg/sq. m, into the 2nd vial - adriamycin 50 mg/sq. m to be incubated for 30 min at 37 C and intravenously injected by drops for patients. Simultaneously, the intake of prednisolone should be prescribed at the dosage of 60 mg/sq. m since the 1st d and during the next 5 d and preductal at the dosage of 105 mg daily during a week, and then 2 wk more at the dosage of 60 mg daily. All the procedures should be repeated in above-mentioned sequence 4-6 times. The method enables to decrease toxic manifestations of chemotherapy while applying adequate dosages of cytostatics, anthracycline antibiotics, among them, at no great manifestations of their toxicity due to preductal's cardioprotective action.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: medicine, cardiology.

SUBSTANCE: it is suggested to apply cortisol antagonists in addition to clonidine while manufacturing preparation to treat heart failure. Moreover, one should introduce cortisol antagonist or a product that includes cortisol antagonist along with the second medicinal preparation being a combined preparation to be applied either simultaneously, separately or successively. The present innovation provides decreased symptoms of heart failure at decreasing cardiac muscle's fibrosis and heart sizes due to preferable impact upon glucocorticoid receptors in patient's heart and/or kidneys.

EFFECT: higher efficiency of application.

12 cl, 2 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate being equivalent to 0.3% free foundation, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent - benzalconium chloride and a s a stabilizer - the salt of disodium ethylenediamine tetraacetic acid, moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalconium chloride, ciprofloxacin hydrochloride. Then one should perform the control for the quality of obtained solution to be then filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at creating the pressure in an eye and at certain desired osmolality.

EFFECT: higher efficiency of therapy.

4 cl, 1 ex

Endoparasitic agent // 2250779

FIELD: medicine.

SUBSTANCE: invention relates to endoparasitic agent containing cyclic depsipeptide of general formula 1 and piperazine of formula 2 .

EFFECT: endoparasitic agent with synergetic agent.

6 cl, 7 ex, 7 tbl

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating oncological diseases. It is suggested to apply bisdioxopiperazine (previously known as cardioprotector) to either treat or prevent tissue lesions caused due to sporadic transudation of cytotoxic poison for topoisomerase II (represented by anthracyclines, etoposide, teniposide, mitoxantrone daunorubicin, doxorubicin, etc.), medicinal remedies and pharmaceutical set of the same indication. It is, also, suggested to apply the method to treat or prevent tissue lesions caused by sporadic transudation of topoisomerase II poison. BisdioxopiperazineICRF-187 has impact due to catalytic inhibiting topo II. Signs for possible transudation of topoisomerase II poison (of local toxicity) usually include the availability of acute pain, erythema, development of ulcerations in area of transudation; due to the action of ICRF-187 the quantity of wounds is reduced, or the development of side effects is not observed.

EFFECT: higher efficiency of therapy.

59 cl, 12 dwg, 13 ex, 10 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of adamantane of the general formula:

wherein m = 1 or 2; each R1 represents independently hydrogen atom; A represents C(O)NH or NHC(O); Ar represents the group:


wherein X represents a bond, oxygen atom or group CO, (CH2)1-6, CH=, O(CH2)1-6, O(CH2)2-6O, O(CH2)2-3O(CH2)1-3, CR'(OH), NR5, (CH2)1-6NR5, CONR5, S(O)n, S(O)nCH2, CH2S(O)n wherein n = 0, 1 or 2; R' represents hydrogen atom; one of R2 and R3 represents halogen atom, nitro-group, (C1-C6)-alkyl; and another is taken among R2 and R3 and represents hydrogen or halogen atom; either R4 represents 3-9-membered saturated or unsaturated aliphatic heterocyclic ring system comprising one or two nitrogen atoms and oxygen atom optionally being heterocyclic ring system is substituted optionally with one or more substitutes taken independently among hydroxyl atoms, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl, -NR6R7, -(CH2)rNR6R7; or R4 represents 3-8-membered saturated carbocyclic ring system substituted with one or more substitutes taken independently among -NR6R7, -(CH2)NR6R7 wherein r = 1; R5 represents hydrogen atom; R6 and R7 each represents independently hydrogen atom or (C1-C6)-alkyl, or (C2-C6)-hydroxyalkyl group eliciting antagonistic effect with respect to R2X7-receptors. Also, invention describes a method for their preparing, pharmaceutical composition comprising thereof, a method for preparing the pharmaceutical composition and their applying in therapy for treatment of rheumatic arthritis and obstructive diseases of respiratory ways.

EFFECT: improved method for preparing and treatment, valuable medicinal properties of compounds.

13 cl, 88 ex

FIELD: medicine.

SUBSTANCE: at performing curative endoscopy one should apply pneumoapplication of granulated sorbent - diovine at the quantity of 0.2 g, the pressure being 15 atm. at the distance of 1.5 cm against the defect onto the surface of bleeding rupture of gastric mucosa. Diovine's coarse-grained structure enables to keep the integrity of mucous-bicarbonate barrier due to providing normal vapor exchange and moisture medium in the defect. Moreover, diovine's antimicrobial action helps to suppress gram-positive and gram-negative microflora that enables to shorten terms for defects healing and decrease the frequency of repeated hemorrhages.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes a medicinal formulation consisting of a core and the stomach-dissolving envelope. The core comprises trimetazidine dihydrochloride as an active component, and starch, mannitol, povidone, magnesium stearate, croscarmelose and microcrystalline cellulose as accessory substances. The envelope comprises hydroxypropylmethylcellulose, polyethylene glycol, titanium dioxide, magnesium stearate and acid red as a dye. Also, invention describes a method for making the trimetazidine medicinal formulation. Trimetazidine tablets show high mechanical strength in the low pressing strength (3.5-5 kH). The composition of the medicinal formulation provides releasing 80% of trimetazidine for 30 min.

EFFECT: improved and valuable properties of formulation.

3 cl, 1 tbl, 1 ex

FIELD: medicine, neurology, pharmacy.

SUBSTANCE: invention proposes using levetiracetam and the corresponding levetiracetam-base pharmaceutical composition used in treatment of bipolar disorders, mania and migraine. Also, invention relates to a pharmaceutical composition based on levetiracetam and at least one inhibitor of GABA type A neuronal receptors that is used in treatment of epilepsy, alcohol withdrawal syndrome, tremor, bipolar disorders, obsessive-compulsive disorder, panic state, depression, headache, pain, ischemia and head trauma, to corresponding methods for treatment, to a method for selective enhancing the therapeutic effect of inhibitors of GABA type A neuronal receptors, to a method for treatment of patient with inhibitor of GABA type A neuronal receptors involving the combined administration of indicated inhibitor of GABA type A neuronal receptors with levetiracetam. Invention shows the possibility for using levetiracetam for treatment of chronic and neuropathic pain in lower doses as compared with doses causing secondary effects, and shows its property to enhance activity of inhibitor of GABA type A neuronal receptors.

EFFECT: improved and valuable medicinal properties of agent.

18 cl, 18 tbl, 7 ex